Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
NCT ID: NCT03779828
Last Updated: 2021-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
11 participants
OBSERVATIONAL
2017-11-27
2019-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Diagnosis is based on clinical presentation and electrophysiological findings in accordance with the EFNS/PNS consensus guidelines. IVIg is the first line treatment witch has been shown to be effective in several placebo-controlled trials.
Once IVIg therapy produces a response and is well tolerated, some patients are able to continue their treatment in the home setting. The HOME LINK system offers an integrated, global solution based on telemonitoring technology providing continuous, remote monitoring of Privigen® infusions administered at home.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcriptome Analysis of the Peripheral Blood in CIDP
NCT02404298
Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
NCT02892890
Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy
NCT01184846
InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT04529291
Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
NCT03967899
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HOME LINK
Telemonitoring system which include web platform and connected devices.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient already receiving home-based treatment with Privigen®
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CSL Behring
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Pellegrin, Bordeaux University Hospital (CHU)
Bordeaux, , France
Hôpital Henri Mondor - APHP
Créteil, , France
Hôpital Roger Salengro - CHRU
Lille, , France
Hôpital Pierre Wertheimer - HCL
Lyon, , France
Hôpital La Timone - APHM
Marseille, , France
Hôpital Gui de Chauliac - Montpellier University Hospital (CHU)
Montpellier, , France
Hôpital Pasteur 2 - Nice University Hospital (CHU)
Nice, , France
Hôpital La Pitié-Salpêtrière - APHP
Paris, , France
Hôpital Lariboisière - APHP
Paris, , France
Hôpital Nord - Saint Etienne University Hospital (CHU)
Saint-Etienne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-A00147-44
Identifier Type: OTHER
Identifier Source: secondary_id
IgPro10_5004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.